Ogawa M, Inagaki J, Horikoshi N, Inoue K, Chinen T, Ueoka H, Nagura E
Cancer Treat Rep. 1979 May;63(5):931-4.
A phase I study of a new anthracycline antibiotic, aclacinomycin A, was performed in a total of 15 patients with advanced malignancy to determine the maximum-tolerated dose. The gastrointestinal toxicity which occurred was not dose-related and was not severe. Epilation and stomatitis were extremely minimal. Both hepatic dysfunction and hematologic toxicity were dose-limiting. A recommended dose for phase II study was determined to be 2.5--3.0 mg/kg (approximately 100--120 mg/m2) given in 3-week intervals. Objective response was observed in two patients with malignant lymphomas.
对15例晚期恶性肿瘤患者进行了一种新型蒽环类抗生素阿克拉霉素A的I期研究，以确定最大耐受剂量。所出现的胃肠道毒性与剂量无关且并不严重。脱发和口腔炎极为轻微。肝功能障碍和血液学毒性均为剂量限制性毒性。确定II期研究的推荐剂量为2.5--3.0毫克/千克（约100--120毫克/平方米），每3周给药一次。在两名恶性淋巴瘤患者中观察到客观缓解。
